255 related articles for article (PubMed ID: 28865741)
21. Risk factors for acquiring extended-spectrum β-lactamase-producing Enterobacteriaceae in geriatric patients with multiple comorbidities in respiratory care wards.
Lin HC; Lai LA; Wu JY; Su YM; Chang SP; Hsueh YM
Geriatr Gerontol Int; 2013 Jul; 13(3):663-71. PubMed ID: 23170823
[TBL] [Abstract][Full Text] [Related]
22. Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis.
Sfeir MM; Askin G; Christos P
Int J Antimicrob Agents; 2018 Nov; 52(5):554-570. PubMed ID: 30081138
[TBL] [Abstract][Full Text] [Related]
23. Noncarbapenems for the Treatment of Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Bacteria.
White CW; Kyle JA; Deas CM; Campbell J
South Med J; 2019 Aug; 112(8):438-443. PubMed ID: 31375841
[TBL] [Abstract][Full Text] [Related]
24. Amikacin therapy for urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli.
Cho SY; Choi SM; Park SH; Lee DG; Choi JH; Yoo JH
Korean J Intern Med; 2016 Jan; 31(1):156-61. PubMed ID: 26767869
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial.
Rattanaumpawan P; Werarak P; Jitmuang A; Kiratisin P; Thamlikitkul V
BMC Infect Dis; 2017 Mar; 17(1):183. PubMed ID: 28249572
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of ESBL-producing Enterobacteriaceae in paediatric urinary tract infections: A systematic review and meta-analysis.
Flokas ME; Detsis M; Alevizakos M; Mylonakis E
J Infect; 2016 Dec; 73(6):547-557. PubMed ID: 27475789
[TBL] [Abstract][Full Text] [Related]
27. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
[TBL] [Abstract][Full Text] [Related]
28. Ertapenem for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing bacteria in children.
Dalgic N; Sancar M; Bayraktar B; Dincer E; Pelit S
Scand J Infect Dis; 2011 May; 43(5):339-43. PubMed ID: 21271945
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcomes of elderly patients with bloodstream infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae in an Italian Internal Medicine ward.
Meini S; Laureano R; Tascini C; Arena F; Fani L; Frullini A; Passaleva MT; Roberts AT; Mannini D; Sbrana F; Ripoli A; Rossolini GM
Eur J Intern Med; 2018 Feb; 48():50-56. PubMed ID: 29089174
[TBL] [Abstract][Full Text] [Related]
30. Risk factors for urinary tract infection caused by Enterobacteriaceae with extended-spectrum beta-lactamase resistance in patients admitted to internal medicine departments.
Vardi M; Kochavi T; Denekamp Y; Bitterman H
Isr Med Assoc J; 2012 Feb; 14(2):115-8. PubMed ID: 22693794
[TBL] [Abstract][Full Text] [Related]
31. Outcome of urinary tract infections caused by extended spectrum β-lactamase-producing Enterobacteriaceae in children.
Tratselas A; Iosifidis E; Ioannidou M; Saoulidis S; Kollios K; Antachopoulos C; Sofianou D; Roilides EJ
Pediatr Infect Dis J; 2011 Aug; 30(8):707-10. PubMed ID: 21248655
[TBL] [Abstract][Full Text] [Related]
32. The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Doi A; Shimada T; Harada S; Iwata K; Kamiya T
Int J Infect Dis; 2013 Mar; 17(3):e159-63. PubMed ID: 23140947
[TBL] [Abstract][Full Text] [Related]
33. Rise of community-onset urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli in children.
Fan NC; Chen HH; Chen CL; Ou LS; Lin TY; Tsai MH; Chiu CH
J Microbiol Immunol Infect; 2014 Oct; 47(5):399-405. PubMed ID: 23834784
[TBL] [Abstract][Full Text] [Related]
34. Temocillin versus carbapenems for urinary tract infection due to ESBL-producing Enterobacteriaceae: a multicenter matched case-control study.
Delory T; Gravier S; Le Pluart D; Gaube G; Simeon S; Davido B; Piet E; Lepeule R; Lesprit P; Lafaurie M
Int J Antimicrob Agents; 2021 Jul; 58(1):106361. PubMed ID: 34000372
[TBL] [Abstract][Full Text] [Related]
35. Inappropriate empirical antibiotic therapy does not adversely affect the clinical outcomes of patients with acute pyelonephritis caused by extended-spectrum β-lactamase-producing Enterobacteriales.
Kim SH; Oh S; Huh K; Cho SY; Kang CI; Chung DR; Peck KR
Eur J Clin Microbiol Infect Dis; 2019 May; 38(5):937-944. PubMed ID: 30868326
[TBL] [Abstract][Full Text] [Related]
36. Clinical and economic impact of urinary tract infections caused by ESBL-producing Escherichia coli requiring hospitalization: A matched cohort study.
Esteve-Palau E; Solande G; Sánchez F; Sorlí L; Montero M; Güerri R; Villar J; Grau S; Horcajada JP
J Infect; 2015 Dec; 71(6):667-74. PubMed ID: 26380898
[TBL] [Abstract][Full Text] [Related]
37. Pediatric Febrile Urinary Tract Infection Caused by ESBL Producing
Agegnehu A; Worku M; Nigussie D; Lulu B; Tadesse BT
Biomed Res Int; 2020; 2020():6679029. PubMed ID: 34692824
[TBL] [Abstract][Full Text] [Related]
38. Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems.
Fukuchi T; Iwata K; Kobayashi S; Nakamura T; Ohji G
BMC Infect Dis; 2016 Aug; 16(1):427. PubMed ID: 27538488
[TBL] [Abstract][Full Text] [Related]
39. Retrospective assessment of antimicrobial stewardship initiative in outpatient use of ertapenem for uncomplicated extended spectrum beta lactamase Enterobacteriaceae urinary tract infections.
Wong CP; Delate T; Hudson E; Nguyen JK; Yang SJ; Abraham M
BMC Infect Dis; 2021 Aug; 21(1):823. PubMed ID: 34399680
[TBL] [Abstract][Full Text] [Related]
40. Extended spectrum β-lactamase producing enterobacteriaceae: carbapenem sparing options.
Aslan AT; Akova M
Expert Rev Anti Infect Ther; 2019 Dec; 17(12):969-981. PubMed ID: 31722185
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
